Merck & Co., Inc. filings document the regulatory record of a New Jersey pharmaceutical issuer with common stock and multiple debt securities registered on the New York Stock Exchange. The company's disclosures cover operating and financial results, clinical and regulatory matters, material agreements, governance matters and capital-structure changes.
Merck's SEC record includes Form 8-K material-event reports, definitive proxy materials and debt-financing disclosures. Recent filings describe underwritten public offerings of notes, registered securities, shareholder voting matters, board and executive-governance information, and other events tied to the company's pharmaceutical, vaccine and animal health businesses.
Thomas H. Glocer, a director of Merck & Co., Inc. (MRK), reported transactions dated 09/30/2025. The filing shows a disposition of 5,100 shares of Merck common stock in the non-derivative section. In the derivative section, Mr. Glocer acquired 580.8412 phantom stock units on the same date; those units are to be settled 100% in cash upon his termination of service under the referenced deferred compensation plan. The phantom units represent 580.8412 underlying common shares with an indicated price of $83.93, and the report lists 105,645.8965 shares beneficially owned following the transactions. The form is signed by an attorney-in-fact for Mr. Glocer on 10/02/2025. The filing notes that holdings include shares acquired through dividend reinvestment.
Mary Ellen Coe, identified as a director of Merck & Co. (MRK), reported transactions dated 09/30/2025. The filing shows a disposition of 10 shares of Merck common stock and the acquisition of 357.4407 phantom stock units, each unit representing one share. The phantom units are tied to 357.4407 shares with a reference price of $83.93. The report lists total beneficial ownership following the transactions as 28,684.663 shares. The phantom units are to be settled 100% in cash upon the reporting person's termination of service under the plan's distribution schedule. The filing also notes holdings include shares from dividend reinvestment.
Merck & Co., Inc. completed an underwritten public offering of new investment-grade debt across multiple maturities. The company issued $500,000,000 of Floating Rate Notes due 2027, $750,000,000 of 3.850% Notes due 2027, $750,000,000 of 4.150% Notes due 2030, $1,000,000,000 of 4.550% Notes due 2032, $1,750,000,000 of 4.950% Notes due 2035, and $1,250,000,000 of 5.700% Notes due 2055 under an existing shelf registration. All notes were issued under Merck’s longstanding indenture with U.S. Bank Trust National Association, and the filing also attaches officers’ certificates and a legal opinion related to the new series.
Merck & Co., Inc. is offering multiple series of unsecured notes totaling up to $6.0 billion across maturities from 2027 to 2055. The offering includes $500 million of floating rate notes maturing September 15, 2027 and five fixed-rate series: $750 million 3.850% due 2027, $750 million 4.150% due 2030, $1.0 billion 4.550% due 2032, $1.75 billion 4.950% due 2035 and $1.25 billion 5.700% due 2055. The notes are unsecured and will rank pari passu with other unsecured indebtedness and be structurally subordinated to liabilities of subsidiaries; as of June 30, 2025 certain subsidiaries had $5.7 billion of indebtedness and guaranteed $1.0 billion of parent debt. The floating rate notes reference Compounded SOFR and include detailed benchmark transition and replacement provisions; the prospectus warns of SOFR volatility, limited history and potential adverse effects if benchmark replacement occurs. The fixed-rate notes pay semiannual interest and may be optionally redeemed by the issuer under specified Treasury-rate-based formulas. The notes will be issued in book-entry form through DTC.
Merck & Co., Inc. prospectus supplement describes an offering of multiple series of unsecured notes, including floating rate notes tied to Compounded SOFR and several fixed-rate series. The notes will be issued in global, book-entry form through DTC and will not be listed on an exchange; currently there is no public market. The issuer is a finance subsidiary whose obligations will be unsecured and effectively junior to any secured debt and structurally subordinated to non‑guarantor subsidiaries' liabilities. The prospectus details SOFR-related volatility and benchmark transition risks, optional redemption mechanics for fixed-rate series, customary transfer and payment procedures, defeasance features, restrictive covenants (including limits on secured debt and sale-leaseback transactions) and events of default. Several key economic terms (aggregate sizes, exact interest rates, specific maturity dates and settlement dates) are redacted in the provided text.
Merck & Co., Inc. filed a Form 13F reporting its institutional holdings. The Form 13F information table total value is $215,600,331. The report was signed by Kelly Grez, Corporate Secretary on 08-13-2025 and lists Merck Sharp & Dohme LLC as an included manager.
Merck & Co. (MRK) Form 4 – 5 Aug 2025: EVP & Chief Information & Digital Officer David M. Williams reported the vesting of 17,119 restricted stock units (RSUs) on 4 Aug 2025 (code M). The shares were issued at the market price of $79.29 and immediately reduced by 8,432 shares (code F) that the issuer withheld to cover tax obligations. Net increase to Williams’s direct ownership is +8,687 shares, bringing his total direct holding to 33,013.467 shares. The related RSU grant is now fully settled; no derivative securities remain.
The footnote clarifies a prior filing error: the RSUs were previously disclosed as vesting in three annual tranches, but actually vested in one installment on 4 Aug 2025. No other transactions, sales to the open market, or new option grants were disclosed.
Merck & Co., Inc. (NYSE: MRK) filed an 8-K disclosing two key items. Item 2.02 furnishes, but does not file, the company’s Q2-25 earnings press release (Ex. 99.1) and related supplemental information (Ex. 99.2); specific financial figures are not included in this filing.
Item 2.05 launches a new “2025 Restructuring Program.” Approved 25 Jul 2025, the plan targets sales, administrative and R&D head-count reductions, a smaller real-estate footprint and continued manufacturing network optimization. Merck expects:
- Total pretax charges: ≈ $3.0 billion; ~60 % cash (severance & contract terminations) and the balance non-cash (accelerated depreciation).
- Major actions largely finished by end-2027; manufacturing actions substantially done by end-2029.
- Annual cost savings: ≈ $1.7 billion realized by end-2027.